Recombinant Mycobacterium bovis bacillus calmette-guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques

Jaimie D. Sixsmith, Michael W. Panas, Sunhee Lee, Geoffrey O. Gillard, Keri Ann White, Michelle A. Lifton, Harikrishnan Balachandran, Linh Mach, John P. Miller, Christy Lavine, C. Todd De Marco, Georgia D. Tomaras, Connie Gee, Steven A. Porcelli, Michelle H. Larsen, Richard Frothingham, Joern E. Schmitz, William R. Jacobs, Barton F. Haynes, Norman L. Letvin & 1 others Birgit Korioth-Schmitz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Live attenuated nonpathogenic Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediates long-lasting immune responses, has been safely administered as a tuberculosis vaccine to billions of humans, and is affordable to produce as a vaccine vector. These characteristics make it very attractive as a human immunodeficiency virus (HIV) vaccine vector candidate. Here, we assessed the immunogenicity of recombinant BCG (rBCG) constructs with different simian immunodeficiency virus (SIV)gag expression cassettes as priming agents followed by a recombinant replication-incompetent New York vaccinia virus (NYVAC) boost in rhesus macaques. Unmutated rBCG constructs were used in comparison to mutants with gene deletions identified in an in vitro screen for augmented immunogenicity. We demonstrated that BCG-SIVgag is able to elicit robust transgene-specific priming responses, resulting in strong SIV epitope-specific cellular immune responses. While enhanced immunogenicity was sustained at moderate levels for>1 year following the heterologous boost vaccination, we were unable to demonstrate a protective effect after repeated rectal mucosal challenges with pathogenic SIVmac251. Our findings highlight the potential for rBCG vaccines to stimulate effective cross-priming and enhanced major histocompatibility complex class I presentation, suggesting that combining this approach with other immunogens may contribute to the development of effective vaccine regimens against HIV. Copyright

Original languageEnglish (US)
Pages (from-to)1385-1395
Number of pages11
JournalClinical and Vaccine Immunology
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Bacilli
Mycobacterium bovis
Macaca mulatta
Viruses
Bacillus
Vaccines
Tuberculosis Vaccines
HIV
Cross-Priming
BCG Vaccine
Synthetic Vaccines
Vaccinia virus
Gene Deletion
Major Histocompatibility Complex
Transgenes
Cellular Immunity
Epitopes
Vaccination
Genes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Clinical Biochemistry
  • Microbiology (medical)

Cite this

Recombinant Mycobacterium bovis bacillus calmette-guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. / Sixsmith, Jaimie D.; Panas, Michael W.; Lee, Sunhee; Gillard, Geoffrey O.; White, Keri Ann; Lifton, Michelle A.; Balachandran, Harikrishnan; Mach, Linh; Miller, John P.; Lavine, Christy; De Marco, C. Todd; Tomaras, Georgia D.; Gee, Connie; Porcelli, Steven A.; Larsen, Michelle H.; Frothingham, Richard; Schmitz, Joern E.; Jacobs, William R.; Haynes, Barton F.; Letvin, Norman L.; Korioth-Schmitz, Birgit.

In: Clinical and Vaccine Immunology, Vol. 21, No. 10, 01.10.2014, p. 1385-1395.

Research output: Contribution to journalArticle

Sixsmith, JD, Panas, MW, Lee, S, Gillard, GO, White, KA, Lifton, MA, Balachandran, H, Mach, L, Miller, JP, Lavine, C, De Marco, CT, Tomaras, GD, Gee, C, Porcelli, SA, Larsen, MH, Frothingham, R, Schmitz, JE, Jacobs, WR, Haynes, BF, Letvin, NL & Korioth-Schmitz, B 2014, 'Recombinant Mycobacterium bovis bacillus calmette-guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques', Clinical and Vaccine Immunology, vol. 21, no. 10, pp. 1385-1395. https://doi.org/10.1128/CVI.00324-14
Sixsmith, Jaimie D. ; Panas, Michael W. ; Lee, Sunhee ; Gillard, Geoffrey O. ; White, Keri Ann ; Lifton, Michelle A. ; Balachandran, Harikrishnan ; Mach, Linh ; Miller, John P. ; Lavine, Christy ; De Marco, C. Todd ; Tomaras, Georgia D. ; Gee, Connie ; Porcelli, Steven A. ; Larsen, Michelle H. ; Frothingham, Richard ; Schmitz, Joern E. ; Jacobs, William R. ; Haynes, Barton F. ; Letvin, Norman L. ; Korioth-Schmitz, Birgit. / Recombinant Mycobacterium bovis bacillus calmette-guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques. In: Clinical and Vaccine Immunology. 2014 ; Vol. 21, No. 10. pp. 1385-1395.
@article{0ba8c93c56734450a49de4be726448cf,
title = "Recombinant Mycobacterium bovis bacillus calmette-gu{\'e}rin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques",
abstract = "Live attenuated nonpathogenic Mycobacterium bovis bacillus Calmette-Gu{\'e}rin (BCG) mediates long-lasting immune responses, has been safely administered as a tuberculosis vaccine to billions of humans, and is affordable to produce as a vaccine vector. These characteristics make it very attractive as a human immunodeficiency virus (HIV) vaccine vector candidate. Here, we assessed the immunogenicity of recombinant BCG (rBCG) constructs with different simian immunodeficiency virus (SIV)gag expression cassettes as priming agents followed by a recombinant replication-incompetent New York vaccinia virus (NYVAC) boost in rhesus macaques. Unmutated rBCG constructs were used in comparison to mutants with gene deletions identified in an in vitro screen for augmented immunogenicity. We demonstrated that BCG-SIVgag is able to elicit robust transgene-specific priming responses, resulting in strong SIV epitope-specific cellular immune responses. While enhanced immunogenicity was sustained at moderate levels for>1 year following the heterologous boost vaccination, we were unable to demonstrate a protective effect after repeated rectal mucosal challenges with pathogenic SIVmac251. Our findings highlight the potential for rBCG vaccines to stimulate effective cross-priming and enhanced major histocompatibility complex class I presentation, suggesting that combining this approach with other immunogens may contribute to the development of effective vaccine regimens against HIV. Copyright",
author = "Sixsmith, {Jaimie D.} and Panas, {Michael W.} and Sunhee Lee and Gillard, {Geoffrey O.} and White, {Keri Ann} and Lifton, {Michelle A.} and Harikrishnan Balachandran and Linh Mach and Miller, {John P.} and Christy Lavine and {De Marco}, {C. Todd} and Tomaras, {Georgia D.} and Connie Gee and Porcelli, {Steven A.} and Larsen, {Michelle H.} and Richard Frothingham and Schmitz, {Joern E.} and Jacobs, {William R.} and Haynes, {Barton F.} and Letvin, {Norman L.} and Birgit Korioth-Schmitz",
year = "2014",
month = "10",
day = "1",
doi = "10.1128/CVI.00324-14",
language = "English (US)",
volume = "21",
pages = "1385--1395",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Recombinant Mycobacterium bovis bacillus calmette-guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques

AU - Sixsmith, Jaimie D.

AU - Panas, Michael W.

AU - Lee, Sunhee

AU - Gillard, Geoffrey O.

AU - White, Keri Ann

AU - Lifton, Michelle A.

AU - Balachandran, Harikrishnan

AU - Mach, Linh

AU - Miller, John P.

AU - Lavine, Christy

AU - De Marco, C. Todd

AU - Tomaras, Georgia D.

AU - Gee, Connie

AU - Porcelli, Steven A.

AU - Larsen, Michelle H.

AU - Frothingham, Richard

AU - Schmitz, Joern E.

AU - Jacobs, William R.

AU - Haynes, Barton F.

AU - Letvin, Norman L.

AU - Korioth-Schmitz, Birgit

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Live attenuated nonpathogenic Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediates long-lasting immune responses, has been safely administered as a tuberculosis vaccine to billions of humans, and is affordable to produce as a vaccine vector. These characteristics make it very attractive as a human immunodeficiency virus (HIV) vaccine vector candidate. Here, we assessed the immunogenicity of recombinant BCG (rBCG) constructs with different simian immunodeficiency virus (SIV)gag expression cassettes as priming agents followed by a recombinant replication-incompetent New York vaccinia virus (NYVAC) boost in rhesus macaques. Unmutated rBCG constructs were used in comparison to mutants with gene deletions identified in an in vitro screen for augmented immunogenicity. We demonstrated that BCG-SIVgag is able to elicit robust transgene-specific priming responses, resulting in strong SIV epitope-specific cellular immune responses. While enhanced immunogenicity was sustained at moderate levels for>1 year following the heterologous boost vaccination, we were unable to demonstrate a protective effect after repeated rectal mucosal challenges with pathogenic SIVmac251. Our findings highlight the potential for rBCG vaccines to stimulate effective cross-priming and enhanced major histocompatibility complex class I presentation, suggesting that combining this approach with other immunogens may contribute to the development of effective vaccine regimens against HIV. Copyright

AB - Live attenuated nonpathogenic Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediates long-lasting immune responses, has been safely administered as a tuberculosis vaccine to billions of humans, and is affordable to produce as a vaccine vector. These characteristics make it very attractive as a human immunodeficiency virus (HIV) vaccine vector candidate. Here, we assessed the immunogenicity of recombinant BCG (rBCG) constructs with different simian immunodeficiency virus (SIV)gag expression cassettes as priming agents followed by a recombinant replication-incompetent New York vaccinia virus (NYVAC) boost in rhesus macaques. Unmutated rBCG constructs were used in comparison to mutants with gene deletions identified in an in vitro screen for augmented immunogenicity. We demonstrated that BCG-SIVgag is able to elicit robust transgene-specific priming responses, resulting in strong SIV epitope-specific cellular immune responses. While enhanced immunogenicity was sustained at moderate levels for>1 year following the heterologous boost vaccination, we were unable to demonstrate a protective effect after repeated rectal mucosal challenges with pathogenic SIVmac251. Our findings highlight the potential for rBCG vaccines to stimulate effective cross-priming and enhanced major histocompatibility complex class I presentation, suggesting that combining this approach with other immunogens may contribute to the development of effective vaccine regimens against HIV. Copyright

UR - http://www.scopus.com/inward/record.url?scp=84907519311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907519311&partnerID=8YFLogxK

U2 - 10.1128/CVI.00324-14

DO - 10.1128/CVI.00324-14

M3 - Article

VL - 21

SP - 1385

EP - 1395

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 10

ER -